MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a late-stage pharmaceutical company focused on the development of potential new therapies for cancer. MEI Pharma's portfolio of drug candidates includes multiple clinical-stage assets, including zandelisib, which is currently in clinical trials that may support marketing approval by the U.S. Food and Drug Administration and other regulatory agencies worldwide. Each of MEI Pharma’s pipeline candidates has a unique mechanism of action that targets pathways driving various hematologic malignancies and/or solid tumors. Our approach is to fully understand and leverage the mechanisms and properties of our drug candidates to optimize the balance between efficacy and tolerability, best addressing the needs of cancer patients.